Relationship between clinical parameters and pharmacokinetics of mitomycin C

J. Verweij, J. den Hartigh, M. Stuurman, J. de Vries, H. M. Pinedo

Research output: Contribution to journalArticle

Abstract

Although the number of reports on mitomycin C (MMC) pharmacokinetics is increasing, data on possible relations between clinical parameters and pharmacokinetics are usually lacking. The present report concenrns the results of a detailed study on this subject in 35 patients receiving MMC, either as a single agent or as a part of combination chemotherapy. MMC concentrations were determined by HPLC. T1/2β varied from 23 to 78 min, VD from 11 to 48 l/m2, Cltot from 12 to 42 l/h per m2, and AUC from 138 to 1221 μg/h per l, confirming previously reported data. Infusion time, cholestasis, and urinary pH did not influence the pharmacokinetic data. There were no relations between other clinical data and pharmacokinetics, nor between AUC and bone marrow toxicity. An interaction between MMC and furosemide could not be excluded, but there was no interaction with other comedication. Consecutive pharmacokinetics in 6 patients showed consistent results. Because renal impairment does not alter MMC pharmacokinetics and renal excretion is not a major route of elimination, it is suggested that renal impairment does not call for dose adjustment.

Original languageEnglish (US)
Pages (from-to)91-94
Number of pages4
JournalJournal of Cancer Research and Clinical Oncology
Volume113
Issue number1
DOIs
Publication statusPublished - Feb 1987
Externally publishedYes

    Fingerprint

Keywords

  • Mitomycin C
  • Pharmacokinetics

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this